#WCCardio
LightNews LightNews
accintouch.bsky.social
🚀 #ACC27-#WCCardio Early Bird Registration Now Open!

The global CV community is coming together in Houston for breakthrough science, practical education and worldwide collaboration.

📍 Houston | April 10-12, 2027

Register by Dec. 2 to save ➡️ https://bit.ly/3N7hU5j #CardioSky
October 28, 2026 at 5:51 PM
accintouch.bsky.social
Join the global CV community April 10-12, 2027, in Houston, TX, for #ACC27-#WCCardio. Explore the latest breakthroughs, guidelines & clinical insights while connecting with colleagues from around the world. 🌎

Exclusive #ACCMember Registration is now open! 🔗 https://bit.ly/4nbj2kJ #CardioSky
October 24, 2026 at 8:50 PM
accintouch.bsky.social
🥁 The ACC is now accepting submissions of LBCTs. Submit your research for a chance to be featured on cardiology's main stage & help shape the future of CV medicine by sharing your research with the global CV community at #ACC27-#WCCardio.

🔎 Learn more: https://bit.ly/3JNubKG #CardioSky
October 20, 2026 at 4:05 PM
accintouch.bsky.social
Ready for your research to make an impact? Submit your abstract or case for #ACC27-#WCCardio and connect your work with leading experts and peers from around the world in Houston.

📢 Deadline Extended: Submissions close Thursday, Oct. 8, at 1 p.m. ET. ➡️ https://bit.ly/4pH6yn6 #CardioSky
October 5, 2026 at 10:55 PM
accintouch.bsky.social
🎥 "Bring us your science." - #ACCPresident Dr. Roxana Mehran

Dr. Mehran invites you to submit abstracts across 60 topics, complex clinical cases & CV Team abstracts & cases for a chance to present at #ACC27-#WCCardio.

⏰ Submit by Oct. 6 at 1 p.m. ET. ➡️ https://bit.ly/4pH6yn6 #CardioSky
September 30, 2026 at 5:44 PM
accintouch.bsky.social
🚀 Your mission starts now: Submit your science for #ACC27-#WCCardio! Be part of the 🌍 stage where groundbreaking discoveries, real-world cases & innovative ideas come together to advance CV care.

Submissions are due Tuesday, Oct. 6, at 1 p.m. ET. ➡️ https://bit.ly/4iMRZxh
September 22, 2026 at 4:58 PM
accintouch.bsky.social
Visit the ACC booth at ACC Latin America 2026 to pick up your promo code to SAVE 25% on your ACC.27-WCC registration! https://bit.ly/4pmLf9M

#ACCLATAM #ACCIntl #ACC27-#WCCardio #CardioSky
September 18, 2026 at 4:12 PM
accintouch.bsky.social
🚀 Houston, get ready. The world of cardiology is coming.

ACC President Roxana Mehran, MD, FACC, invites you to join her at #ACC27 Together With #WCCardio (April 10-12, 2027) in Houston, TX.

📆 Save the date, 🔬 submit your science & ✈️ see you there: https://bit.ly/4gKu2nV

#CardioSky
August 31, 2026 at 4:59 PM
accintouch.bsky.social
🚀 Launch your science at #ACC27-#WCCardio!

The countdown is on for ACC.27-WCC in Houston, TX, April 10-12, 2027. Share your research & help shape the future of CV medicine with the global 🫀 community.

Abstract & Case Submissions now open. Submit by Oct. 6. https://t.co/RNHJVNbVGy

#CardioSky
https://bit.ly/4pH6yn6
t.co
August 29, 2026 at 11:22 PM
accintouch.bsky.social
📣 #ACC27-#WCCardio Abstract & Case Submissions Now Open!

Transform the future of CV medicine by sharing your research with the 🌎 CV community at ACC.27-WCC, taking place April 10-12, 2027, in Houston, TX!

Submit your science by Tuesday, Oct. 6 ➡️ https://bit.ly/4pH6yn6 #CardioSky #MedSky
August 29, 2026 at 8:04 PM
accintouch.bsky.social
🌎 Ready to showcase your science on a global stage? Apply for the Young Investigator Awards and present your work at #ACC27-#WCCardio.

🩺 Clinical Investigations
🧬 Basic & Translational Science
📊 Outcomes Research

Learn more & apply by Aug. 14 👉 https://bit.ly/4v9f4wP
August 10, 2026 at 5:12 PM
anastasiasmihaili.bsky.social
#ESCCongress #WCCardio brings great #science #innovation but it is the #friendships which fill my ♥️ with joy.

I am grateful to many friends who have connected #MadeMyDay 🙏

Thank you @angelamaas.bsky.social for a wonderful evening ♥️
August 31, 2025 at 7:15 AM
jamacardiology.com
From @jama.com: Among patients with acute myocardial infarction, routine screening for Helicobacter pylori did not significantly reduce upper gastrointestinal bleeding.

#ESCCongress #WCCardio

ja.ma/4mNNYIs
A graph titled 'Upper Gastrointestinal Bleeding in Cluster Periods With Routine Helicobacter pylori Screening vs Usual Care' plots cumulative hazard against time in years. Two lines represent 'H pylori screening' and 'Usual care'.
September 1, 2025 at 1:30 PM
jamacardiology.com
In this secondary analysis of the AZALEA-TIMI 71 RCT, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function.

#ESCCongress #WCCardio

ja.ma/47m94sm
JAMA Cardiology publication titled "Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function" includes graphs comparing bleeding events across creatinine clearance levels for Rivaroxaban and Abelacimab.
September 1, 2025 at 12:35 PM
jamacardiology.com
From @jama.com: Among patients with acute myocardial infarction, routine screening for Helicobacter pylori did not significantly reduce upper gastrointestinal bleeding.

#ESCCongress #WCCardio

ja.ma/4mQMbly
Graph from JAMA article titled, "Helicobacter pylori Screening After Acute Myocardial Infarction". Plots cumulative hazard of upper gastrointestinal bleeding over time, comparing H pylori screening vs. usual care. Screening shows slightly lower bleeding rates.
September 1, 2025 at 6:35 AM
jamacardiology.com
@jama.com: Among patients w/ NSTEMI and multivessel disease, FFR-guided complete revascularization reduced risk of death, nonfatal myocardial infarction, revascularization, and stroke at 1 year compared with culprit-only revascularization.

#ESCCongress #WCCardio

ja.ma/3VqoBQB
JAMA article displays a graph titled 'Primary Outcome' comparing 'Culprit-only revascularization' and 'Complete revascularization' over 12 months. The former shows a higher cumulative probability of death, myocardial infarction, or stroke.
August 31, 2025 at 3:45 PM
jamacardiology.com
@jama.com Editorial: Discontinuing anticoagulation therapy after AF ablation may be beneficial for patients at intermediate stroke risk and high bleeding risk, although careful monitoring and shared decision-making are essential.
#ESCCongress #WCCardio
ja.ma/45GLNAf
JAMA article, "Lifelong Anticoagulation After AF Ablation—Time to Reconsider?" by Edward P. Gerstenfeld, MD; Xiang Wen Lee, MBBS. Discusses stroke risk, atrial fibrillation(AF), and anticoagulation therapy.
August 31, 2025 at 3:35 PM
jamacardiology.com
From @jama.com: In patients without atrial arrhythmia recurrence after AF ablation, discontinuing oral anticoagulant therapy reduced the composite risk of stroke, systemic embolism, and major bleeding compared with continued therapy.

#ESCCongress #WCCardio

ja.ma/4lQ7LWc
JAMA: Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation. Graph shows cumulative incidence for stroke, embolism, & major bleeding. Oral anticoagulant vs. no oral anticoagulant groups over 24 months.
August 31, 2025 at 3:30 PM
jamacardiology.com
From @jamanetworkopen.com: Despite advances in trial design, women are underrepresented in cardiovascular research, especially for high-risk conditions like arrhythmias, coronary heart disease, and acute coronary syndrome.

#ESCCongress #WCCardio

ja.ma/45TKJYw
JAMA Network Open article: "Participation of Women in Cardiovascular Trials From 2017 to 2023 A Systematic Review". Includes 2 line graphs showing Median Participation: Prevalence Ratio in Cardiovascular Trials.
August 31, 2025 at 1:45 PM
jamacardiology.com
From @jama.com: In patients w cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no additional benefit over semaglutide.

#ESCCongress #WCCardio

ja.ma/4nbWuRk
Flowchart outlining a study on Semaglutide and Tirzepatide for heart failure. It shows patient filtering and eligibility criteria in emulated trials and expanded populations. The study includes patients initiating semaglutide, tirzepatide, or sitagliptin across the US.
August 31, 2025 at 1:30 PM
jamacardiology.com
From @jamanetworkopen.com: Despite advances in trial design, women are underrepresented in cardiovascular research, especially for high-risk conditions like arrhythmias, coronary heart disease, and acute coronary syndrome.

#ESCCongress #WCCardio

ja.ma/4lV7hy2
JAMA Network Open article: "Participation of Women in Cardiovascular Trials From 2017 to 2023, A Systematic Review." Includes two graphs showing median participation prevalence ratio trends for CV conditions and risk factors.
August 31, 2025 at 8:55 AM
jamacardiology.com
From @jama.com: In patients w cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no additional benefit over semaglutide.

#ESCCongress #WCCardio

ja.ma/4lTu4ub
Flowchart titled "Study Design Overview" compares Semaglutide and Tirzepatide for heart failure patients. It details patient enrollment, filtering criteria (STEP-HFpEF DM, SUMMIT), and eligibility. The study includes emulated trials and expanded populations.
August 31, 2025 at 7:15 AM
jamacardiology.com
Among patients with severe symptomatic aortic stenosis at low to intermediate surgical risk, transcatheter aortic valve implantation was associated with a lower 1-year risk of all-cause death or any stroke.

#ESCCongress #WCCardio

ja.ma/4p0FhM2
JAMA Cardiology presents research on aortic stenosis treatment. A graph shows cumulative incidence (%) over time (months) for SAVR (orange) and TAVI (blue), with sHR 0.73. Data includes 'No. at risk' for each group. Published August 30, 2025.
August 30, 2025 at 3:30 PM
jamacardiology.com
Editorial: Schuermans et al's study links clonal hematopoiesis (CHIP) to acute inflammatory heart conditions, suggesting that CHIP mutations could serve as key biomarkers for predisposition to chronic and acute cardiac diseases.

#ESCCongress #WCCardio

ja.ma/47Dk5Wz
JAMA Cardiology editorial: "Clonal Hematopoiesis—Fuel to Inflame the Heart" by Domingo A. Pascual-Figal, PhD; Jose J. Fuster, PhD. Discusses CHIP as a risk factor for cardiovascular disease and its link to inflammation.
August 30, 2025 at 3:10 PM
jamacardiology.com
Among middle-aged adults, clonal hematopoiesis of indeterminate potential (CHIP) was linked to an increased risk of developing myocarditis and pericarditis.

#ESCCongress #WCCardio

ja.ma/45RBaJG
A graph titled Figure 1. Cumulative Incidence of Myocarditis and Pericarditis During Follow-Up by Clonal Hematopoiesis of Indeterminate Potential (CHIP) Status displays three lines: Large CHIP, Any CHIP, and No CHIP, charting cumulative incidence over follow-up time.
August 30, 2025 at 3:00 PM